Balance Sheet
Accounts PayablesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNotes PayablesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Universe Pharmaceuticals (UPC) Raw Materials (2021 - 2025)

Universe Pharmaceuticals' Raw Materials history spans 5 years, with the latest figure at $2.5 billion for Q3 2025.

  • On a quarterly basis, Raw Materials rose 245.78% to $2.5 billion in Q3 2025 year-over-year; TTM through Sep 2025 was $2.5 billion, a 245.78% increase, with the full-year FY2025 number at $2.5 billion, up 245.78% from a year prior.
  • Raw Materials hit $2.5 billion in Q3 2025 for Universe Pharmaceuticals, up from $720.0 million in the prior quarter.
  • Over the last five years, Raw Materials for UPC hit a ceiling of $2.5 billion in Q3 2025 and a floor of $16701.0 in Q3 2022.
  • Historically, Raw Materials has averaged $642.6 million across 5 years, with a median of $2.7 million in 2021.
  • Biggest five-year swings in Raw Materials: plummeted 99.39% in 2022 and later surged 113221.79% in 2024.
  • Tracing UPC's Raw Materials over 5 years: stood at $2.7 million in 2021, then plummeted by 99.39% to $16701.0 in 2022, then skyrocketed by 3704.53% to $635395.0 in 2023, then surged by 113221.79% to $720.0 million in 2024, then skyrocketed by 245.78% to $2.5 billion in 2025.
  • Business Quant data shows Raw Materials for UPC at $2.5 billion in Q3 2025, $720.0 million in Q3 2024, and $635395.0 in Q3 2023.